Moderna has no 'visible path' to profitability, analyst says скачать в хорошем качестве

Moderna has no 'visible path' to profitability, analyst says

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight. Spikevax, the company's COVID-19 vaccine, managed to bring in $3.1 billion across 2024. "While there is the Merck (MRK) cancer vaccine, the Phase 3 CMV vaccine, and the norovirus vaccine, the CMV vaccine has been delayed. The data has not hit, and they sound like they're pushing it out to later this year," Yee says on the other vaccine projects Jefferies is "cautiously optimistic" on. Yee also comments on the tightening GLP-1 weight-loss drug race between Eli Lilly (LLY), Novo Nordisk (NVO), and Amgen (AMGN). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. #youtube #stocks #news About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. Get the latest news and data at finance.yahoo.com Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) Follow Yahoo Finance on social: X:   / yahoofinance   Instagram: https://www.instagram.com/yahoofinanc... TikTok: https://www.tiktok.com/@yahoofinance?... Facebook:   / yahoofinance   LinkedIn:   / yahoo-finance